

**Malaria Surveillance —
United States, 1992**

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Centers for Disease Control
and Prevention (CDC)
Atlanta, Georgia 30333



The *MMWR* series of publications is published by the Epidemiology Program Office, Centers for Disease Control and Prevention (CDC), Public Health Service, U.S. Department of Health and Human Services, Atlanta, GA 30333.

SUGGESTED CITATION

General: Centers for Disease Control and Prevention. *CDC Surveillance Summaries*, October 20, 1995. MMWR 1995;44(No. SS-5).
Specific: [Author(s)]. [Title of particular article]. In: *CDC Surveillance Summaries*, October 20, 1995. MMWR 1995;44(No. SS-5):[inclusive page numbers].

Centers for Disease Control and Prevention David Satcher, M.D., Ph.D.
Director

The production of this report as an *MMWR* serial publication was coordinated in:

Epidemiology Program Office..... Stephen B. Thacker, M.D., M.Sc.
Director

Richard A. Goodman, M.D., M.P.H.
Editor, MMWR Series

Scott F. Wetterhall, M.D., M.P.H.
Associate Editor, CDC Surveillance Summaries

Scientific Information and Communications Program

CDC Surveillance Summaries Suzanne M. Hewitt, M.P.A.
Managing Editor

Lanette B. Wolcott
Project Editor

Sandra L. Ford
Morie M. Higgins
Beverly J. Holland
Peter M. Jenkins

Visual Information Specialists

Use of trade names and commercial sources is for identification only and does not imply endorsement by the Public Health Service or the U.S. Department of Health and Human Services.

Copies can be purchased from Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402-9325. Telephone: (202) 783-3238.

Contents

Reports Published in <i>CDC Surveillance Summaries</i> Since January 1, 1985	ii
Malaria Surveillance — United States, 1992	1
Introduction.....	2
Methods.....	2
Results	4
Discussion	14
References.....	15
Appendix A: Microscopic Procedures for Diagnosing Malaria	16
State and Territorial Epidemiologists and Laboratory Directors	Inside back cover

Reports Published in *CDC Surveillance Summaries* Since January 1, 1985

Subject	Responsible CIO/Agency*	Most Recent Report
Abortion	NCCDPHP	1995; Vol. 44, No. SS-2
AIDS/HIV		
Distribution by Racial/Ethnic Group	NCID	1988; Vol. 37, No. SS-3
Among Black & Hispanic Children & Women of Childbearing Age	NCEHC	1990; Vol. 39, No. SS-3
Behavioral Risk Factors	NCCDPHP	1991; Vol. 40, No. SS-4
Birth Defects		
B.D. Monitoring Program (see also Malformations)	NCEH	1993; Vol. 42, No. SS-1
Contribution of B.D. to Infant Mortality		
Among Minority Groups	NCEHC	1990; Vol. 39, No. SS-3
Breast & Cervical Cancer	NCCDPHP	1992; Vol. 41, No. SS-2
<i>Campylobacter</i>	NCID	1988; Vol. 37, No. SS-2
Chancroid	NCPS	1992; Vol. 41, No. SS-3
Chlamydia	NCPS	1993; Vol. 42, No. SS-3
Cholera	NCID	1992; Vol. 41, No. SS-1
Congenital Malformations, Minority Groups	NCEHC	1988; Vol. 37, No. SS-3
Contraception Practices	NCCDPHP	1992; Vol. 41, No. SS-4
Cytomegalovirus Disease, Congenital	NCID	1992; Vol. 41, No. SS-2
Dengue	NCID	1994; Vol. 43, No. SS-2
Dental Caries & Periodontal Disease Among Mexican-American Children	NCPS	1988; Vol. 37, No. SS-3
Diabetes Mellitus	NCCDPHP	1993; Vol. 42, No. SS-2
Dracunculiasis	NCID	1992; Vol. 41, No. SS-1
Ectopic Pregnancy	NCCDPHP	1993; Vol. 42, No. SS-6
Elderly, Hospitalizations Among	NCCDPHP	1991; Vol. 40, No. SS-1
Endometrial & Ovarian Cancers	EPO, NCCDPHP	1986; Vol. 35, No. 2SS
<i>Escherichia coli</i> O157	NCID	1991; Vol. 40, No. SS-1
Evacuation Camps	EPO	1992; Vol. 41, No. SS-4
Family Planning Services at Title X Clinics	NCCDPHP	1995; Vol. 44, No. SS-2
Foodborne Disease	NCID	1990; Vol. 39, No. SS-1
Gonorrhea & Syphilis, Teenagers	NCPS	1993; Vol. 42, No. SS-3
Hazardous Substances Emergency Events	ATSDR	1994; Vol. 43, No. SS-2
Health Surveillance Systems	IHPO	1992; Vol. 41, No. SS-4
Hepatitis	NCID	1985; Vol. 34, No. 1SS
Homicide	NCEHC	1992; Vol. 41, No. SS-3
Homicides, Black Males	NCEHC	1988; Vol. 37, No. SS-1
Hysterectomy	NCCDPHP	1986; Vol. 35, No. 1SS
Infant Mortality (see also National Infant Mortality; Birth Defects; Postneonatal Mortality)	NCEHC	1990; Vol. 39, No. SS-3
Influenza	NCID	1993; Vol. 42, No. SS-1
Injury		
Death Rates, Blacks & Whites	NCEHC	1988; Vol. 37, No. SS-3
Drownings	NCEHC	1988; Vol. 37, No. SS-1
Falls, Deaths	NCEHC	1988; Vol. 37, No. SS-1
Firearm-Related Deaths, Unintentional	NCEHC	1988; Vol. 37, No. SS-1
Head & Neck	NCIPC	1993; Vol. 42, No. SS-5
In Developing Countries	NCEHC	1992; Vol. 41, No. SS-1

***Abbreviations**

ATSDR	Agency for Toxic Substances and Disease Registry
CIO	Centers/Institute/Offices
EPO	Epidemiology Program Office
IHPO	International Health Program Office
NCCDPHP	National Center for Chronic Disease Prevention and Health Promotion
NCEH	National Center for Environmental Health
NCEHC	National Center for Environmental Health and Injury Control
NCID	National Center for Infectious Diseases
NCIPC	National Center for Injury Prevention and Control
NCPS	National Center for Prevention Services
NIOSH	National Institute for Occupational Safety and Health

Reports Published in *CDC Surveillance Summaries* Since January 1, 1985 — Continued

Subject	Responsible CIO/Agency*	Most Recent Report
In the Home, Persons <15 Years of Age	NCEHIC	1988; Vol. 37, No. SS-1
Motor Vehicle-Related Deaths	NCEHIC	1988; Vol. 37, No. SS-1
Objectives of Injury Control, State & Local	NCEHIC	1988; Vol. 37, No. SS-1
Objectives of Injury Control, National	NCEHIC	1988; Vol. 37, No. SS-1
Residential Fires, Deaths	NCEHIC	1988; Vol. 37, No. SS-1
Tap Water Scalds	NCEHIC	1988; Vol. 37, No. SS-1
Lead Poisoning, Childhood	NCEHIC	1990; Vol. 39, No. SS-4
Low Birth Weight	NCCDPHP	1990; Vol. 39, No. SS-3
Malaria	NCID	1995; Vol. 44, No. SS-5
Maternal Mortality	NCCDPHP	1991; Vol. 40, No. SS-2
Measles	NCPS	1992; Vol. 41, No. SS-6
Meningococcal Disease	NCID	1993; Vol. 42, No. SS-2
Mining	NIOSH	1986; Vol. 35, No. 2SS
Mumps	NCID	1995; Vol. 44, No. SS-3
National Infant Mortality (see also Infant Mortality; Birth Defects)	NCCDPHP	1989; Vol. 38, No. SS-3
<i>Neisseria gonorrhoeae</i> , Antimicrobial Resistance in	NCPS	1993; Vol. 42, No. SS-3
Neural Tube Defects	NCEH	1995; Vol. 44, No. SS-4
Nosocomial Infection	NCID	1986; Vol. 35, No. 1SS
Occupational Injuries/Disease		
Asthma	NIOSH	1994; Vol. 43, No. SS-1
Hazards, Occupational	NIOSH	1985; Vol. 34, No. 2SS
In Meatpacking Industry	NIOSH	1985; Vol. 34, No. 1SS
Silicosis	NIOSH	1993; Vol. 42, No. SS-5
State Activities	NIOSH	1987; Vol. 36, No. SS-2
Parasites, Intestinal	NCID	1991; Vol. 40, No. SS-4
Pediatric Nutrition	NCCDPHP	1992; Vol. 41, No. SS-7
Pertussis	NCPS	1992; Vol. 41, No. SS-8
Plague	NCID	1985; Vol. 34, No. 2SS
Plague, American Indians	NCID	1988; Vol. 37, No. SS-3
Poliomyelitis	NCPS	1992; Vol. 41, No. SS-1
Postneonatal Mortality	NCCDPHP	1991; Vol. 40, No. SS-2
Pregnancy Nutrition	NCCDPHP	1992; Vol. 41, No. SS-7
Pregnancy, Teenage	NCCDPHP	1993; Vol. 42, No. SS-6
Rabies	NCID	1989; Vol. 38, No. SS-1
Racial/Ethnic Minority Groups	Various	1990; Vol. 39, No. SS-3
Respiratory Disease	NCEHIC	1992; Vol. 41, No. SS-4
Rotavirus	NCID	1992; Vol. 41, No. SS-3
<i>Salmonella</i>	NCID	1988; Vol. 37, No. SS-2
Sexually Transmitted Diseases in Italy	NCPS	1992; Vol. 41, No. SS-1
Smoking	NCCDPHP	1990; Vol. 39, No. SS-3
Smoking-Attributable Mortality	NCCDPHP	1994; Vol. 43, No. SS-1
Tobacco-Use Behaviors	NCCDPHP	1994; Vol. 43, No. SS-3
Streptococcal Disease (Group B)	NCID	1992; Vol. 41, No. SS-6
Sudden Unexplained Death Syndrome Among Southeast Asian Refugees	NCEHIC, NCPS	1987; Vol. 36, No. 1SS
Suicides, Persons 15–24 Years of Age	NCEHIC	1988; Vol. 37, No. SS-1
Syphilis, Congenital	NCPS	1993; Vol. 42, No. SS-6
Syphilis, Primary & Secondary	NCPS	1993; Vol. 42, No. SS-3
Tetanus	NCPS	1992; Vol. 41, No. SS-8
Trichinosis	NCID	1991; Vol. 40, No. SS-3
Tuberculosis	NCPS	1991; Vol. 40, No. SS-3
Waterborne Disease Outbreaks	NCID	1993; Vol. 42, No. SS-5
Years of Potential Life Lost	EPO	1992; Vol. 41, No. SS-6
Youth Risk Behaviors	NCCDPHP	1995; Vol. 44, No. SS-1

Malaria Surveillance — United States, 1992

Jane R. Zucker, M.D., M.Sc.
Ann M. Barber
Lynn A. Paxton, M.D., M.P.H.
Linda J. Schultz, D.V.M.
Hans O. Lobel, M.D., M.P.H.
Jacqueline M. Roberts, M.S.
Mary E. Bartlett
Carlos C. Campbell, M.D., M.P.H.

*Division of Parasitic Diseases
National Center for Infectious Diseases*

Abstract

Problem/Condition: Malaria is caused by one of four species of *Plasmodium* (i.e., *P. falciparum*, *P. vivax*, *P. ovale*, or *P. malariae*) and is transmitted by the bite of an infective female *Anopheles* sp. mosquito. Most malaria cases in the United States occur among persons who have traveled to areas that have ongoing transmission. However, cases are transmitted occasionally through exposure to infected blood products, by congenital transmission, or by local mosquito-borne transmission. Malaria surveillance is conducted to identify episodes of local transmission and to guide prevention recommendations.

Reporting Period Covered: Cases with onset of illness during 1992.

Description of System: Malaria cases were identified at the local level (i.e., by health-care providers or through laboratory-based surveillance). All suspected cases were confirmed by slide diagnosis and then reported to the respective state health department and to CDC.

Results: CDC received reports of 910 cases of malaria that had onset of symptoms during 1992 among persons in the United States and its territories. In comparison, 1,046 cases were reported for 1991, representing a decrease of 13% in 1992. *P. vivax*, *P. falciparum*, *P. malariae*, and *P. ovale* were identified in 51%, 33%, 4%, and 3% of cases, respectively. The species was not identified in the remaining 9% of cases. The number of reported malaria cases that had been acquired in Africa by U.S. civilians decreased 38%, primarily because the number of *P. falciparum* cases declined. Of U.S. civilians whose illnesses were diagnosed as malaria, 81% had not taken a chemoprophylactic regimen recommended by CDC. Seven patients had acquired their infections in the United States. Seven deaths were attributed to malaria.

Interpretation: The decrease in the number of *P. falciparum* cases in U.S. civilians could have resulted from a change in travel patterns, reporting errors, or increased use of more effective chemoprophylaxis regimens.

Actions Taken: Additional information was obtained concerning the seven fatal cases and the seven cases acquired in the United States. Malaria prevention guidelines were updated and disseminated to health-care providers. Persons traveling to a malaria-endemic area should take the recommended chemoprophylaxis regimen and use personal protection measures to prevent mosquito bites. Any person who has been to a

malarious area and who subsequently develops a fever or influenza-like symptoms should seek medical care, which should include a blood smear for malaria. The disease can be fatal if not diagnosed and treated at an early stage of infection. Recommendations concerning prevention and treatment of malaria can be obtained from CDC.

INTRODUCTION

Malaria is caused by infection with one of four *Plasmodium* species (i.e., *P. falciparum*, *P. vivax*, *P. ovale*, and *P. malariae*) that can infect humans. The infection is transmitted by the bite of an infective female *Anopheles* sp. mosquito. Forty percent of the world's population live in areas where malaria is transmitted (e.g., parts of Africa, Asia, Central America, Hispaniola, North America, Oceania, and South America). In the past, malaria was endemic throughout much of the continental United States; more than an estimated 600,000 cases occurred during 1914 (1). During the late 1940s, a combination of improved socioeconomic conditions, water management, vector-control efforts, and case management was successful at interrupting malaria transmission in the United States. Since then, surveillance has been maintained to detect reintroduction of transmission.

Through 1992, almost all cases of malaria in the United States were imported from regions of the world where malaria transmission was known to occur. Each year, several cases that had been acquired in the United States either by blood-induced or congenital transmission were reported. In addition, cases that might have been mosquito-borne infections acquired in the United States were occasionally reported.

State and/or local health departments and CDC thoroughly investigate all locally acquired malaria cases, and CDC conducts an analysis of all imported cases to detect trends in acquisition. This information is used to guide malaria prevention recommendations for persons who travel abroad. For example, an increase in *P. falciparum* malaria among U.S. travelers to Africa, an area with increasing chloroquine-resistance, led CDC in 1990 to change the recommended chemoprophylaxis from chloroquine to mefloquine (2).

The signs and symptoms of malaria illness are variable, but most patients experience fever. Other symptoms often include headache, back pain, chills, increased sweating, myalgia, nausea, vomiting, diarrhea, and cough. The diagnosis of malaria should be considered for any person who has these symptoms and who has traveled to an area that has malaria transmission. Untreated *P. falciparum* infection can progress to coma, renal failure, pulmonary edema, and death. Asymptomatic parasitemia can occur among persons who have been long-term residents of malaria-endemic areas. This report summarizes malaria cases reported to CDC for 1992.

METHODS

Sources of Data

Malaria surveillance is a passive system; cases are identified at the local level by health-care providers and/or laboratories. All suspected cases are confirmed by slide diagnosis. A slide-confirmed case is reported to the state health department and to CDC on a standard form that contains clinical, laboratory, and epidemiologic

information. CDC staff review all reporting forms at the time of receipt and request additional information if necessary (e.g., when travel to a malaria-endemic country was not reported). Reports of other cases are telephoned directly by health-care providers to CDC, usually when assistance with diagnosis or treatment is requested. All cases that have been acquired in the United States are investigated, including all induced and congenital cases and possible introduced or cryptic cases. Information from uniform case report forms is entered into a data base and analyzed annually.

Definition of Terms

The following definitions are used in this report:

- **Laboratory criteria for diagnosis:** Demonstration of malaria parasites in blood films.
- **Confirmed case:** Symptomatic or asymptomatic illness that occurs in the United States in a person who has microscopically confirmed malaria parasitemia, regardless of whether the person had previous attacks of malaria while in other countries. A subsequent attack of malaria occurring in a person is counted as an additional case if the demonstrated *Plasmodium* species differs from the initially identified species. A subsequent attack of malaria occurring in a person while in the United States could indicate a relapsing infection or treatment failure resulting from drug resistance if the demonstrated *Plasmodium* species is the same species identified previously.*

This report also uses terminology derived from the recommendations of the World Health Organization (WHO) (3). Definitions of the following terms are included for reference.

- **Autochthonous malaria:**
 - Indigenous.** Malaria acquired by mosquito transmission in an area where malaria occurs regularly.
 - Introduced.** Malaria acquired by mosquito transmission from an imported case in an area where malaria does not occur regularly.
- **Imported malaria:** Malaria acquired outside a specific area. In this report, imported cases are those acquired outside the United States and its territories.
- **Induced malaria:** Malaria acquired through artificial means (e.g., blood transfusion, common syringes, or malariotherapy).
- **Relapsing malaria:** Renewed manifestation (i.e., of clinical symptoms and/or parasitemia) of malarial infection that is separated from previous manifestations of the same infection by an interval greater than those caused by the usual periodicity of the paroxysms.

*To obtain confirmation diagnosis of blood smears from questionable cases and to obtain appropriate treatment recommendations, contact either your state or local health department or CDC's National Center for Infectious Diseases, Division of Parasitic Diseases, Malaria Section; telephone (770) 488-7760.

- **Cryptic malaria:** An isolated malaria case that cannot be linked epidemiologically to secondary cases.

Microscopic Diagnosis of Malaria

The early diagnosis of malaria requires that physicians consider malaria in the differential diagnosis of every patient who has a fever; the examination of such patients should include taking a comprehensive travel history. If malaria is suspected, a Giemsa-stained smear of the patient's peripheral blood should be examined for parasites. Thick and thin blood smears must be prepared properly because the accuracy of diagnosis depends on the quality of the blood film and the experience of the laboratory personnel. (See Appendix A for proper procedures necessary for accurately diagnosing malaria.)

RESULTS

General Surveillance

CDC received reports of 910 malaria cases that had onset of symptoms during 1992 among persons in the United States and its territories. In comparison, 1,046 cases were reported for 1991 (4). In 1992, seven of the 910 persons acquired the infection in the United States.

Most of the malaria cases reported each year since 1973 have occurred in civilians (Table 1). In 1992, 394 cases occurred in U.S. civilians, representing a 33% decrease in the 585 cases reported for 1991 (Figure 1). However, the number of cases in foreign civilians increased 10%, from 439 cases in 1991 to 481 cases in 1992. Only 29 cases occurred in U.S. military personnel during 1992.

Plasmodium Species

The *Plasmodium* species was identified in 826 (91%) of the 910 cases. In 1992, *P. vivax* and *P. falciparum* were identified in blood from 51% and 33% of infected persons, respectively (Table 2). The 296 *P. falciparum* cases reported for 1992 represented a 28% decrease from the 410 cases reported for 1991.

Area of Acquisition and of Onset of Illness

Most malaria cases had been acquired in Africa (337 [37%] cases) and Asia (330 [36%] cases) (Table 3). In the United States, cases were reported by the state in which the disease was diagnosed (Figure 2).

Interval Between Arrival and Illness

Of those persons who became ill with malaria after arriving in the United States, the interval between the dates of arrival and the onset of illness was known for 554 of the persons for whom the infecting *Plasmodium* species was also identified. The infecting species was not identified for an additional 41 cases. Clinical malaria developed within 1 month after the person's arrival in 175 (88%) of the 198 *P. falciparum* cases and in 100 (32%) of the 316 *P. vivax* cases (Table 4). Only 16 (3%) of the 554 persons became ill ≥ 1 year after their arrival in the United States. An additional 40 persons reported becoming ill before arriving in the United States. Half of these persons

developed symptoms within 1 week before arrival; the remainder reported that symptoms began 7–105 days before arrival.

Imported Malaria Cases

Imported Malaria in Military Personnel

Twenty-nine cases of imported malaria in U.S. military personnel were reported for 1992. Twenty-one of these cases occurred in personnel of the U.S. Army; four cases, the U.S. Marine Corps; two cases, the National Guard; one case, the U.S. Air Force; and one case, the U.S. Navy.

TABLE 1. Number of malaria cases* in U.S. and foreign civilians and U.S. military personnel — United States, 1966–1992

Year	U.S. military personnel	U.S. civilians	Foreign civilians	Unknown	Total
1966	621	89	32	22	764
1967	2,699	92	51	15	2,857
1968	2,567	82	49	0	2,698
1969	3,914	90	47	11	4,062
1970	4,096	90	44	17	4,247
1971	2,975	79	69	57	3,180
1972	454	106	54	0	614
1973	41	103	78	0	222
1974	21	158	144	0	323
1975	17	199	232	0	448
1976	5	178	227	5	415
1977	11	233	237	0	481
1978	31	270	315	0	616
1979	11	229	634	3	877
1980	26	303	1,534	1	1,864
1981	21	273	809	0	1,103
1982	8	348	574	0	930
1983	10	325	468	0	803
1984	24	360	632	0	1,016
1985	31	446	568	0	1,045
1986	35	410	646	0	1,091
1987	23	421	488	0	932
1988	33	550	440	0	1,023
1989	35	591	476	0	1,102
1990	36	558	504	0	1,098
1991	22	585	439	0	1,046
1992	29	394	481	6	910

*A case was defined as symptomatic or asymptomatic illness that occurs in the United States in a person who has microscopically confirmed malaria parasitemia, regardless of whether the person had previous attacks of malaria while in other countries. A subsequent attack of malaria occurring in a person is counted as an additional case if the demonstrated *Plasmodium* species differs from the initially identified species. A subsequent attack of malaria occurring in a person while in the United States could indicate a relapsing infection or treatment failure resulting from drug resistance if the demonstrated *Plasmodium* species is the same species identified previously.


Imported Malaria in Civilians

Of the 868 imported malaria cases in civilians, 387 (45%) occurred in U.S. citizens and 481 (55%) in citizens of other countries (Table 5). Of the 387 imported malaria cases in U.S. civilians, 190 (49%) had been acquired in Africa (Table 5), representing a 38% decline in the 308 imported cases acquired in that region during 1991. Eighty-nine (23%) of the imported cases reported for 1992 had been acquired in Asia. Of the 481 imported cases in foreign civilians, 233 (48%) had been acquired in Asia and 142 (30%) in Africa.

Use of Chemoprophylaxis

Information concerning use of chemoprophylaxis was known for 349 (90%) of the 387 U.S. civilians who had imported malaria. Of these 349 persons, 178 (51%) had not taken chemoprophylaxis, 104 (30%) had not taken a drug recommended by CDC for

FIGURE 1. Number of malaria cases in U.S. and foreign civilians — United States,* 1966–1992



*Includes Puerto Rico, the Virgin Islands, and Guam.

TABLE 2. Number of malaria cases, by *Plasmodium* species — United States, 1991 and 1992

<i>Plasmodium</i> species	1991		1992	
	No.	(%)	No.	(%)
<i>P. vivax</i>	453	(43.3)	463	(50.9)
<i>P. falciparum</i>	410	(39.2)	296	(32.5)
<i>P. malariae</i>	62	(5.9)	39	(4.3)
<i>P. ovale</i>	24	(2.3)	28	(3.1)
Undetermined	97	(9.3)	84	(9.2)
Total	1,046	(100.0)	910	(100.0)

the area visited, and only 67 (19%) had taken the correct medication as recommended by CDC (5). Of these 67 cases, 37 were consistent with relapse infections caused by *P. vivax* or *P. ovale*, and 17 cases could not be assessed because of incomplete information. Of the remaining 13 persons who reported having taken the correct medication, four persons had taken the recommended dosage and nine persons had not.

The purpose of travel to foreign countries with known malaria transmission was reported for 278 (72%) of the 387 U.S. civilians who had imported malaria cases. Of the 387 civilians, the largest percentage (14%) had traveled to visit friends and relatives (Table 6).


Malaria Acquired in the United States

Congenital Malaria

The following four cases of congenitally acquired malaria were reported for 1992.

Case 1. During February 1992, a 3-week-old boy was admitted to a hospital in California because of febrile episodes. An examination of the infant's blood smear demonstrated the presence of *P. vivax* parasites. He was treated with chloroquine, and his recovery was uneventful.

FIGURE 2. Number of malaria cases, by state in which the disease was diagnosed* — United States, 1992



*Of the total 910 malaria cases that were reported during 1992, only seven cases had been acquired in the United States. Four of these cases had been acquired congenitally, and three had been acquired through blood transfusions.

TABLE 3. Number of malaria cases, by *Plasmodium* species and area of acquisition — United States, 1992

Area of acquisition	<i>Plasmodium</i> species						Total
	<i>P. vivax</i>	<i>P. falciparum</i>	<i>P. malariae</i>	<i>P. ovale</i>	Mixed	Unknown	
AFRICA	38	221	15	27	0	36	337
Algeria	0	0	0	0	0	2	2
Angola	0	4	0	0	0	0	4
Benin	1	1	0	0	0	0	2
Burkina Faso	0	2	0	0	0	0	2
Cameroon	0	11	0	0	0	0	11
Central African Republic	1	1	0	0	0	0	2
Chad	0	1	0	0	0	0	1
Djibouti	0	1	0	0	0	0	1
Egypt	1	0	0	0	0	0	1
Equatorial Guinea	0	1	0	0	0	1	2
Ethiopia	1	1	0	0	0	0	2
Gambia	1	1	0	0	0	0	2
Ghana	3	14	2	1	0	1	21
Guinea	0	2	0	0	0	0	2
Ivory Coast	1	9	0	0	0	0	10
Kenya	5	12	4	2	0	4	27
Liberia	0	12	3	3	0	2	20
Madagascar	1	2	0	0	0	0	3
Malawi	0	1	0	0	0	0	1
Mali	0	4	0	1	0	0	5
Mauritania	1	0	0	0	0	0	1
Niger	0	1	0	0	0	0	1
Nigeria	6	88	3	6	0	10	113
Rwanda	1	0	0	1	0	0	2
Senegal	0	1	0	1	0	0	2
Sierra Leone	0	11	0	3	0	3	17
South Africa	0	1	0	0	0	1	2
Tanzania	0	3	0	0	0	1	4
Togo	0	2	0	2	0	0	4
Uganda	0	6	0	2	0	0	8
Zaire	1	1	0	1	0	0	3
Zambia	0	3	1	0	0	0	4
Zimbabwe	0	1	0	0	0	0	1
Africa, Central*	1	0	0	0	0	0	1
Africa, East*	7	5	1	2	0	1	16
Africa, South*	1	0	0	0	0	0	1
Africa, West*	0	9	0	0	0	1	10
Africa, Unspecified*	5	9	1	2	0	9	26
ASIA	242	50	10	0	0	28	330
Afghanistan	0	0	0	0	0	1	1
Cambodia	32	17	1	0	0	11	61
China	2	2	0	0	0	1	5
India	127	15	6	0	0	9	157
Indonesia	12	2	0	0	0	1	15
Laos	4	0	0	0	0	0	4
Malaysia	0	0	0	0	0	1	1

TABLE 3. Number of malaria cases, by *Plasmodium* species and area of acquisition — United States, 1992 — Continued

Area of acquisition	<i>Plasmodium</i> species						Total
	<i>P. vivax</i>	<i>P. falciparum</i>	<i>P. malariae</i>	<i>P. ovale</i>	Mixed	Unknown	
ASIA (cont'd)	242	50	10	0	0	28	330
Middle East, Unspecified	0	1	0	0	0	0	1
Myanmar (Burma)	1	0	0	0	0	0	1
Pakistan	16	4	0	0	0	1	21
Philippines	7	3	0	0	0	0	10
Sri Lanka	1	0	0	0	0	0	1
Thailand	4	0	0	0	0	0	4
Vietnam	17	3	2	0	0	2	24
Yemen	0	1	0	0	0	0	1
Asia, Southeast*	11	1	1	0	0	1	14
Asia, Unspecified*	8	1	0	0	0	0	9
CENTRAL AMERICA AND CARIBBEAN	114	11	8	0	0	6	139
Belize	3	0	0	0	0	0	3
Costa Rica	5	0	1	0	0	0	6
El Salvador	11	0	2	0	0	0	13
Guatemala	21	1	3	0	0	1	26
Haiti	0	7	0	0	0	1	8
Honduras	45	1	1	0	0	2	49
Nicaragua	4	0	1	0	0	1	6
Panama	1	0	0	0	0	0	1
Central America, Unspecified*	24	2	0	0	0	1	27
NORTH AMERICA	20	3	2	0	0	5	30
Mexico	17	1	0	0	0	5	23
United States	3	2	2	0	0	0	7
SOUTH AMERICA	8	4	0	0	0	2	14
Brazil	1	0	0	0	0	0	1
Colombia	1	1	0	0	0	0	2
Ecuador	1	2	0	0	0	0	3
French Guiana	1	0	0	0	0	0	1
Guyana	1	0	0	0	0	1	2
Venezuela	1	0	0	0	0	1	2
South America, Unspecified*	2	1	0	0	0	0	3
OCEANIA	27	4	3	0	0	2	36
Papua New Guinea	16	3	2	0	0	2	23
Solomon Islands	6	0	1	0	0	0	7
Vanuatu	2	0	0	0	0	0	2
Oceania, Unspecified*	3	1	0	0	0	0	4
Unknown	14	3	1	1	0	5	24
Total	463	296	39	28	0	84	910

* Country unspecified.

His mother had visited Honduras, her native country, during January 1992. An examination of the mother's blood smears also demonstrated the presence of *P. vivax* parasites. She was treated with chloroquine and primaquine.

Case 2. A 5-week-old girl who had been born in California began having febrile episodes during March 1992. The infant remained ill, and she was hospitalized in May because of fever, cough, and lack of appetite. An examination of her blood smear demonstrated the presence of *P. malariae* parasites. She was treated with chloroquine, and her recovery was uneventful.

The infant's mother, a native of Laos, had emigrated to the United States in 1984. She had not traveled to a malarious area since then, and she had not reported having febrile episodes during the pregnancy or delivery. After malaria was diagnosed in the infant, the mother's blood was examined for malaria parasites. Although the mother's blood smear results were negative, her blood sample had a positive reaction with an indirect fluorescent antibody (IFA) assay titer of 1:4,096 for *P. malariae*. She was treated with chloroquine.

Case 3. During May 1992, a 4-week-old boy who had been born in California was hospitalized because of febrile episodes. An examination of the infant's blood smear demonstrated the presence of *P. vivax* parasites. He was treated successfully with chloroquine.

The infant's mother had been born in Mexico and had come to the United States 1 month before delivery. No malaria parasites were detected in her blood smears, and she received presumptive treatment.

Case 4. During June 1992, a 4-week-old girl who had been born in New York was admitted to a hospital in New York City because of fever, splenomegaly, and anemia. An examination of the infant's blood smear demonstrated the presence of *P. vivax* parasites. She received a blood transfusion and was treated with chloroquine; her recovery was uneventful.

The infant's mother, a native of Honduras, had been in the United States since August 1991. The mother had been hospitalized at 37 weeks' gestation because of anemia and thrombocytopenia, and at that time she was diagnosed as having *P. vivax* infection. However, the infant was born before the mother could receive treatment. After the delivery, the mother was treated with chloroquine and primaquine. A post-

TABLE 4. Number of imported malaria cases, by *Plasmodium* species and by interval between date of arrival in the country and onset of illness — United States, 1992

Interval (mos)	<i>Plasmodium</i> species								Total	
	<i>P. vivax</i>		<i>P. falciparum</i>		<i>P. malariae</i>		<i>P. ovale</i>			
	No.	(%)	No.	(%)	No.	(%)	No.	(%)	No.	(%)
<1	100	(31.6)	175	(88.4)	10	(50.0)	1	(5.0)	286	(51.6)
1-2	58	(18.4)	13	(6.6)	3	(15.0)	6	(30.0)	80	(14.4)
3-5	74	(23.4)	7	(3.5)	3	(15.0)	2	(10.0)	86	(15.5)
6-12	72	(22.8)	2	(1.0)	4	(20.0)	8	(40.0)	86	(15.5)
≥13	12	(3.8)	1	(0.5)	0	(0.0)	3	(15.0)	16	(2.9)
Total	316	(100.0)	198	(100.0)	20	(100.0)	20	(100.0)	554	(100.0)

partum examination of the infant's blood smear did not demonstrate the presence of malaria parasites.

Cryptic Malaria

No cases of cryptic malaria were reported for 1992 (6).

Induced Malaria

The following three cases of blood transfusion-induced malaria were reported.

Cases 1 and 2. A 71-year-old female resident of Texas was diagnosed as having idiopathic thrombocytopenic purpura during a 2-week hospitalization in August 1992. She was discharged on August 16 but was readmitted on August 23 because of fever, lethargy, and confusion. An examination of the woman's blood smear demonstrated the presence of *P. falciparum* parasites (approximately 25% of her red blood cells were infected). Although she had not traveled to a malaria-endemic area, she had received a total of 95 units of blood products (5 units of packed red blood cells and 90 units of platelets) during her previous hospitalization.

TABLE 5. Number of imported malaria cases in U.S. and foreign civilians, by area of acquisition — United States, 1992

Area of acquisition	U.S. civilians		Foreign civilians		Total	
	No.	(%)	No.	(%)	No.	(%)
Africa	190	(49.1)	142	(29.5)	332	(38.3)
Asia	89	(23.0)	233	(48.4)	322	(37.1)
Caribbean	2	(0.5)	6	(1.3)	8	(0.9)
Central America	50	(12.9)	62	(12.9)	112	(12.9)
Mexico	4	(1.0)	19	(4.0)	23	(2.7)
Oceania	33	(8.5)	3	(0.6)	36	(4.1)
South America	11	(2.8)	3	(0.6)	14	(1.6)
Unknown	8	(2.1)	13	(2.7)	21	(2.4)
Total	387	(100.0)	481	(100.0)	868	(100.0)

TABLE 6. Number of imported malaria cases in U.S. civilians, by purpose of travel at the time of acquisition — United States, 1992

Category	Imported cases	
	No.	(%)
Business representative	42	(10.9)
Government employee	7	(1.8)
Missionary	41	(10.6)
Peace Corps worker	16	(4.1)
Seaman/Aircrew	2	(0.5)
Teacher/Student	44	(11.4)
Tourist	41	(10.6)
Visiting a friend or relative	55	(14.2)
Other	30	(7.8)
Unknown	109	(28.2)
Total	387	(100.0)

The second case occurred in a 65-year-old male resident of Texas who was diagnosed in August 1992 as having *P. falciparum* infection. He had not traveled to a malaria-endemic area, but he had received 3 units of packed red blood cells for myelodysplasia during August.

Both of these patients (i.e., in cases 1 and 2) had received, during the same time period, blood transfusions in the same city in Texas. The second malaria case was identified while donor recall (i.e., the process of reviewing donor records and contacting each donor for additional information) was being organized for the first case. The review of donor records indicated that none of the donors had provided a history of malaria, malaria treatment, or prophylaxis for malaria, and none had been to a malarious area during the preceding 3 years. However, two donors had contributed blood products to both patients. These two donors were tested for malaria antibodies; a blood sample from one of these donors was negative, but the other donor's blood sample had a positive reaction with an IFA assay titer of 1:4,096 for *P. falciparum* malaria.

The implicated donor was a 19-year-old man who had been born in Nigeria and who had had previous malaria infections. Although he reported symptoms consistent with malaria infection, an examination of his blood smears did not demonstrate the presence of malaria parasites. He had resided in Nigeria through December 1991; at the time of the investigation, he was residing in Utah. He was contacted there by the Utah Department of Health and was treated for *P. falciparum* malaria. One patient (i.e., the patient described in Case 1) had received the donor's platelets; the other patient had received the donor's packed red blood cells.

Case 3. During September 1992, a 44-year-old male resident of California developed renal insufficiency and underwent bilateral nephrectomy. He had had intermittent fevers that had begun in August; in December, he was diagnosed with *P. malariae* infection. He was treated successfully with chloroquine. He had been born in the United States, and he had not traveled to a malaria-endemic area or used intravenous drugs; however, during the 7 months preceding the onset of malarial symptoms, he had received 4 units of packed red blood cells. The four donors of the packed cell units were tested for malaria antibodies. The blood sample of one donor, the patient's brother, was positive for *P. malariae*, with an IFA assay titer of 1:1,024. The implicated unit had been transfused in June 1992. An examination of the brother's blood smears did not demonstrate the presence of malaria parasites.

The brother had been born in Canton Province, China, and he had moved to the United States in 1948 when he was 11 years of age. He had not traveled since then to a malaria-endemic area or reported symptoms suggestive of malaria infection. He was treated with chloroquine.

Deaths Attributed to Malaria

During 1992, the following seven deaths were attributed to malaria.

Case 1. A 22-year-old female resident of Florida had worked for 6 months as a missionary in Mali, at which time she took chloroquine as prophylaxis for malaria. She became ill approximately 2 weeks after she returned home in January 1992, and she was hospitalized 1 week later on January 30. She was diagnosed as having *P. falciparum* infection and was treated with intravenous quinidine and tetracycline.

She developed renal failure and adult respiratory distress syndrome, and she died on February 12.

Case 2. A pregnant resident of New York visited Nigeria with her husband. Her physician had prescribed Fansidar® for her to take during the trip as prophylaxis for malaria. On October 21, 1992, she returned to New York. She developed a fever 5 days later, and she was admitted to the hospital on October 26 when she was at 34 weeks' gestation. Her illness was diagnosed as *P. falciparum* malaria (2% of her red blood cells were infected), and treatment with quinine and clindamycin was initiated. When her clinical condition worsened, her treatment was changed to intravenous quinidine gluconate. She delivered a stillborn infant on October 28, then she became comatose and developed hypotension and respiratory distress. She died on October 30.

Case 3. On September 30, 1992, a 53-year-old man returned to his residence in Alabama after teaching in Burkina Faso. He had not taken prophylaxis for malaria. He became ill 2 days after his return, and he sought medical treatment on October 4. On October 5, his physician diagnosed *P. falciparum* malaria (approximately 15% of his red blood cells were infected) and initiated treatment with oral quinine. The patient could not tolerate oral therapy, and treatment was changed to intravenous quinidine. On October 7, 2 days after starting treatment, he had a grand mal seizure. He died on October 11.

Case 4. A 68-year-old female resident of Mexico had traveled to several countries in Africa, including Kenya, Madagascar, Mauritius, Rwanda, and Uganda. She had taken chloroquine as prophylaxis for malaria during her trip. She arrived in Texas on November 9, where she developed a fever the next day. When she was hospitalized on November 12, approximately 25% of her red blood cells were infected with *P. falciparum*. The patient was treated with intravenous quinidine and an exchange transfusion. She developed multiple complications, including hypotension, renal failure, and adult respiratory distress syndrome. She died on November 21.

Case 5. On November 2, 1992, a 70-year-old male resident of India arrived in California, where he became ill on November 10. When he was hospitalized on November 11, 10% of his red blood cells were infected with *P. falciparum*. At that time, he reported having intermittently taken chloroquine as prophylaxis for malaria while in India. He was treated initially with chloroquine; however, he developed hypoglycemia, mental status changes, and renal failure. Therapy was changed to quinine and doxycycline, then changed again to intravenous quinidine; he also received an exchange transfusion. He died on November 17.

Case 6. On October 23, 1992, a 70-year-old male resident of India came to the United States to visit relatives in Illinois. He became ill on November 2 and was hospitalized on November 9. The illness was diagnosed initially as *P. vivax* infection, and the patient was treated with chloroquine. Further examination of his blood smears demonstrated the presence of *P. falciparum* (10% of his red blood cells were infected), and treatment was changed to intravenous quinidine and doxycycline. The patient, who had not been on prophylaxis for malaria while in India, died on November 13.

Case 7. On July 22, 1992, a 37-year-old male resident of the District of Columbia arrived in New York City after a 15-day trip to Ghana. The patient had been unconscious for 6 hours on the airplane; on arrival in New York, he was febrile, tachycardic, in shock, and intermittently awake. He was transported to a local hospital, where he was treated for multiple organ (including liver and kidney) failure and massive gastrointestinal bleeding and was diagnosed as having *P. falciparum* infection (approximately 5% of his red blood cells were infected). The patient died several hours later on July 23. An autopsy demonstrated sequestration of *P. falciparum* asexual parasites in cerebral vessels consistent with a diagnosis of cerebral malaria. Before his death, the patient had reported having taken an unspecified antimalarial medication.

DISCUSSION

A total of 910 cases of malaria were reported to CDC for 1992, representing a 13% decrease from the 1,046 cases reported for 1991. This decrease primarily reflects the 38% decline in the number of *P. falciparum* infections acquired by U.S. civilians in Africa, an area with chloroquine-resistant *P. falciparum*. This latter decrease could be associated with a) changes in travel patterns, b) disease reporting errors, or c) increased use of the more effective mefloquine regimen. The analysis of cases reported for 1993 will enable further assessment of these factors.

Chemoprophylaxis use was known for 90% of the U.S. civilians who had imported malaria; 81% of these infections occurred in persons who had not taken a chemoprophylactic regimen recommended by CDC. Only four infections occurred in persons who reported having correctly taken the recommended chemoprophylaxis. In 1990, the recommended drug for preventing chloroquine-resistant *P. falciparum* malaria was changed to mefloquine, which is highly effective in comparison with chloroquine, the previously recommended medication (7,8).

An earlier review of deaths in the United States that were attributed to malaria cited multiple causes for such deaths, including failure to take recommended antimalarial chemoprophylaxis, refusal or delay in seeking medical care, and misdiagnosis (9). A combination of these factors contributed to the seven deaths reported for 1992. None of the travelers who died had taken the chemoprophylactic regimens that CDC recommended at the time the person was traveling.

Treatment for malaria should be initiated immediately after the diagnosis has been confirmed by a positive blood smear. Treatment should be determined on the basis of the infecting *Plasmodium* species, the parasite density, and the patient's clinical status (10). Although non-*falciparum* malaria rarely causes severe illness, persons diagnosed as having *P. falciparum* infection are at risk for developing severe life-threatening complications.

Health-care workers are encouraged to consult appropriate sources for malaria treatment recommendations or call CDC's National Center for Infectious Diseases, Division of Parasitic Diseases at (770) 488-7760. Detailed recommendations for preventing malaria are available 24 hours a day by telephone ([404] 332-4555) or facsimile ([404] 332-4565) from the CDC Malaria Hotline. In addition, CDC annually publishes updated recommendations in the *Health Information for International Travel* (5), which is available through the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402-9235; telephone (202) 783-3238.

Acknowledgments

The authors thank the following persons and organizations for providing information described in this surveillance summary: State and local health departments. Personnel of the preventive medicine services of the U.S. Air Force, the U.S. Army, and the U.S. Navy. J.R. Aquirre, Long Beach Department of Health; R.R. Roberto, M.D., Disease Control Section, California Department of Health Services; P. Vaernet, R.N., California Bureau of Disease Control, San Francisco; Valley Medical Center, San Jose, California. E. Bell, R.N., New York City Department of Health; B. Edwards, M.D., Queens Hospital Center, Jamaica, New York. D.A. Waxman, M.D., Wadley Blood Center; S.R. Holms, M.D., Texas Oncology, P.A., Dallas, Texas; K.A. Hendricks, M.D., M.P.H., Texas State Department of Health. C.R. Nichols, M.P.A., Utah Department of Health.

References

1. Pan American Health Organization. Report for registration of malaria eradication from United States of America. Washington, DC: Pan American Health Organization, 1969.
2. Lackritz EM, Lobel HO, Howell J, Bloland P, Campbell CC. Imported *Plasmodium falciparum* malaria in American travelers to Africa: implications for prevention strategies. *JAMA* 1991; 265:383-5.
3. World Health Organization. Terminology of malaria and of malaria eradication. Geneva: World Health Organization, 1963:32.
4. CDC. Malaria surveillance annual summary 1991. Atlanta: US Department of Health and Human Services, Public Health Service, CDC, 1994.
5. CDC. Health information for international travel, 1994. Atlanta: US Department of Health and Human Services, Public Health Service, CDC, 1994; DHHS publication no. (CDC)94-8280.
6. Brook JH, Genese CA, Bloland PB, Zucker JR, Spitalny KC. Malaria probably locally acquired in New Jersey. *N Engl J Med* 1994;331:22-3.
7. Lobel HO, Miani M, Eng T, Bernard KW, Hightower AW, Campbell CC. Long-term malaria prophylaxis with weekly mefloquine. *Lancet* 1993;341:848-51.
8. Steffen R, Fuchs E, Schildknecht J, et al. Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting East Africa. *Lancet* 1993;341:1299-303.
9. Greenberg AE, Lobel HO. Mortality from *Plasmodium falciparum* malaria in travelers from the United States, 1959-1987. *Ann Intern Med* 1990;113:326-7.
10. Zucker JR, Campbell CC. Malaria: principles of prevention and treatment. *Infect Dis Clin North Am* 1993;7:547-67.


APPENDIX A

Microscopic Procedures for Diagnosing Malaria

To establish the diagnosis of malaria, a blood smear must be prepared from fresh finger-prick blood (Figures A-1 and A-2).^{*} The thin smear is fixed in methanol before staining; the thick smear is stained unfixed. Many hospitals have a Wright-Giemsa stain available, which is acceptable; however, Wright stain alone will not reliably stain *Plasmodium* parasites. For best results, the smear should be stained with a 3% Giemsa solution (pH of 7.2) for 30–45 minutes. In *P. falciparum* infections, the parasite density should be estimated by counting the percentage of red blood cells infected—not the number of parasites—under an oil immersion on a thin film.

Thick blood smears are more sensitive in detecting malaria parasites because the blood is concentrated, allowing a greater volume of blood to be examined. However, thick smears are more difficult to read, and thin smears may be preferred by laboratories that have limited experience. *Plasmodium* parasites are always intracellular, and

FIGURE A-1. Blood collection for thin or thick blood film




they demonstrate, if stained correctly, blue cytoplasm with a red chromatin dot. Common errors in reading malaria smears are caused by platelets overlying a red blood cell, concern about missing a positive slide, and misreading artifacts as parasites. Persons suspected of having malaria but whose blood smears do not demonstrate the presence of parasites should have blood smears repeated approximately every 12–24 hours for 3 consecutive days. If smears remain negative, then the diagnosis of malaria is unlikely.

For rapid diagnosis, make the thick and thin films on separate slides. Air dry the thin film, fix it with methyl alcohol, and immediately stain it. If no parasites are found on the thin film, wait until the thick film is dry and examine it for organisms that may not have been detected on the thin preparation.

*In Figures A-1 and A-2, the hands are shown ungloved to better illustrate their placement during the procedures. However, wearing gloves while processing blood specimens is recommended to prevent transmission of bloodborne pathogens (*MMWR* 1988;37:377–82, 387–8 and *MMWR* 1987;36[no. S2]).

FIGURE A-2. Preparation of a thin and thick blood film on the same slide



State and Territorial Epidemiologists and Laboratory Directors

State and Territorial Epidemiologists and Laboratory Directors are acknowledged for their contributions to *CDC Surveillance Summaries*. The epidemiologists listed below were in the positions shown as of June 1995, and the laboratory directors listed below were in the positions shown as of June 1995.

State/Territory	Epidemiologist	Laboratory Director
Alabama	John P. Lofgren, MD	William J. Callan, PhD
Alaska	John P. Middaugh, MD	Gregory V. Hayes
Arizona	Lawrence Sands, DO, MPH	Barbara J. Erickson, PhD
Arkansas	Thomas C. McChesney, DVM	Michael G. Foreman
California	Duc J. Vugia, MD, MPH	Michael G. Volz, PhD
Colorado	Richard E. Hoffman, MD, MPH	Ronald L. Cada, DrPH
Connecticut	James L. Hadler, MD, MPH	Sanders F. Hawkins, PhD
Delaware	A. LeRoy Hathcock, PhD	Mahadeo P. Verma, PhD
District of Columbia	Martin E. Levy, MD, MPH	James B. Thomas, ScD
Florida	Richard S. Hopkins, MD, MSPH	E. Charles Hartwig, ScD
Georgia	Kathleen E. Toomey, MD, MPH	Elizabeth A. Franko, DrPH
Hawaii	Richard L. Vogt, MD	Vernon K. Miyamoto, PhD
Idaho	Jesse F. Greenblatt, MD, MPH	Richard H. Hudson, PhD
Illinois	Byron J. Francis, MD, MPH	David F. Carpenter, PhD
Indiana	Edmundo M. Muniz, MD, PhD, MSc	Barbara Wilder (Acting)
Iowa	M. Patricia Quinlisk, MD, MPH	W. J. Hausler, Jr, PhD
Kansas	Andrew R. Pelletier, MD	Roger H. Carlson, PhD
Kentucky	Reginald Finger, MD, MPH	Thomas E. Maxson, DrPH
Louisiana	Louise McFarland, DrPH	Henry B. Bradford, Jr, PhD
Maine	Kathleen F. Gensheimer, MD, MPH	Philip W. Haines, DrPH
Maryland	Diane M. Dwyer, MD	J. Mehsen Joseph, PhD
Massachusetts	Alfred DeMaria, Jr, MD	Ralph J. Timperi, MPH
Michigan	Kenneth R. Wilcox, Jr, MD, DrPH	Robert Martin, DrPH
Minnesota	Michael T. Osterholm, PhD, MPH	Pauline Bouchard, JD, MPH
Mississippi	Mary Currier, MD, MPH	Joe O. Graves, PhD
Missouri	H. Denny Donnell, Jr, MD, MPH	Eric C. Blank, DrPH
Montana	Todd D. Damrow, PhD, MPH	Douglas O. Abbott, PhD
Nebraska	Thomas J. Safraneck, MD	John D. Blosser
Nevada	Randall L. Todd, DrPH	Arthur F. DiSalvo, MD
New Hampshire	M. Geoffrey Smith, MD, MPH	Veronica C. Malmberg, MSN
New Jersey	Kenneth C. Spitalny, MD	Shahiedy I. Shahied, PhD
New Mexico	C. Mack Sewell, DrPH, MS	Loris W. Hughes, PhD
New York City	Benjamin A. Mojica, MD, MPH	Stanley Reimer
New York State	Dale L. Morse, MD, MS	Lawrence S. Sturman, MD, PhD
North Carolina	Michael Moser, MD, MPH	Samuel N. Merritt, DrPH
North Dakota	Larry A. Shireley, MS, MPH	James D. Anders, MPH
Ohio	Thomas J. Halpin, MD, MPH	Kathleen L. Meckstroth, DrPH
Oklahoma	Joe P. Mallonee, MPH (Acting)	Garry L. McKee, PhD
Oregon	David Fleming, MD	Michael R. Skeels, PhD, MPH
Pennsylvania	James T. Rankin, Jr, DVM, PhD, MPH	Bruce Kieger, DrPH
Rhode Island	Barbara A. DeBuono, MD, MPH	Walter Combs, PhD
South Carolina	James J. Gibson, MD, MPH	Harold Dowda, PhD
South Dakota	Susan E. Lance, DVM, MPH	Richard S. Steece, PhD
Tennessee	Kerry Gateley, MD	Michael W. Kimberly, DrPH
Texas	Diane M. Simpson, MD, PhD	David L. Maserang, PhD
Utah	Craig R. Nichols, MPA	Charles D. Brokopp, DrPH
Vermont	Robert O'Grady (Acting)	Burton W. Wilke, Jr, PhD
Virginia	Grayson B. Miller, Jr, MD	James L. Pearson, DrPH
Washington	Paul Stehr-Green, DrPH, MPH	Jon M. Counts, DrPH
West Virginia	Loretta E. Haddy, MA, MS	Frank W. Lambert, Jr, DrPH
Wisconsin	Jeffrey P. Davis, MD	Ronald H. Laessig, PhD
Wyoming	Gayle L. Miller, DVM, MPH	Carl H. Blank, DrPH
American Samoa	Julia L. Lyons, MD, MPH	—
Federated States of Micronesia	Vacant	—
Guam	Robert L. Haddock, DVM, MPH	Jeff Benjamin (Acting)
Marshall Islands	Tony de Brum	—
Northern Mariana Islands	A. Mark Durand, MD, MPH	—
Palau	Jill McCready, MS, MPH	—
Puerto Rico	Carmen C. Deseda, MD	Adolpho Firpo-Betancourt, MD
Virgin Islands	Donna M. Green, MD	Norbert Mantor, PhD

MMWR

The *Morbidity and Mortality Weekly Report (MMWR)* Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format and on a paid subscription basis for paper copy. To receive an electronic copy on Friday of each week, send an e-mail message to lists@list.cdc.gov. The body content should read *subscribe mmwr-toc*. Electronic copy also is available from CDC's World-Wide Web server at <http://www.cdc.gov/> or from CDC's file transfer protocol server at <ftp.cdc.gov>. To subscribe for paper copy, contact Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone (202) 512-1800.

Data in the weekly *MMWR* are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Address inquiries about the *MMWR* Series, including material to be considered for publication, to: Editor, *MMWR* Series, Mailstop C-08, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333; telephone (404) 332-4555.

All material in the *MMWR* Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.